



EFFECTIVE DATE: 07|01|2012
POLICY LAST UPDATED: 06|19|2018

OVERVIEW

Microwave ablation (MWA) is a technique to destroy tumors and soft tissue by using microwave energy to create thermal coagulation and localized tissue necrosis. MWA is used to treat tumors considered to be inoperable or not amenable to resection or to treat patients ineligible for surgery due to age, presence of comorbidities, or poor general health. MWA may be performed as an open procedure, laparoscopically, percutaneously, or thoracoscopically under image guidance (e.g., ultrasound, computed tomography [CT] or magnetic resonance imaging [MRI]) with sedation, or local or general anesthesia. This technique may also be referred to as microwave coagulation therapy.

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

BlueCHiP for Medicare

Microwave ablation of primary and metastatic tumors is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

Commercial Products

Microwave ablation of primary and metastatic tumors is considered not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

COVERAGE

Benefits may vary between groups/contracts. Please refer to the appropriate section of the Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable not medically necessary/not covered benefits/coverage.

BACKGROUND

Microwave ablation (MWA) is a technique in which the use of microwave energy induces an ultra-high speed, 915 MHz or 2450MHz (2.45GHz), alternating electric field that causes water molecule rotation and the creation of heat. This results in thermal coagulation and localized tissue necrosis. In MWA, a single microwave antenna or multiple antennas connected to a generator are inserted directly into the tumor or tissue to be ablated; energy from the antennas generates friction and heat. The local heat coagulates the tissue adjacent to the probe, resulting in a small, approximately 2-3 cm elliptical area (5 x 3 cm) of tissue ablation. In tumors > 2 cm in diameter, 2-3 antennas may be used simultaneously to increase the targeted area of MWA and shorten operative time. Multiple antennas may also be used simultaneously to ablate multiple tumors. Tissue ablation occurs quickly, within one minute after a pulse of energy, and multiple pulses may be delivered within a treatment session depending on the size of the tumor. The cells killed by MWA are typically not removed but are gradually replaced by fibrosis and scar tissue. If there is local recurrence, it occurs at the edges. Treatment may be repeated as needed. MWA may be used to: 1) control local tumor growth and prevent recurrence; 2) palliate symptoms; and 3) extend survival duration.

Complications from MWA are usually mild and may include pain and fever. Other complications associated with MWA include those caused by heat damage to normal tissue adjacent to the tumor (e.g., intestinal damage during MWA of the kidney or liver), structural damage along the probe track (e.g., pneumothorax as a consequence of procedures on the lung), liver enzyme elevation, liver abscess, ascites, pleural effusion, diaphragm injury, or secondary tumors if cells seed during probe removal. MWA should be avoided in pregnant patients since potential risks to the patient and/or fetus have not been established and in patients with implanted electronic devices (e.g. implantable pacemakers) that may be adversely affected by microwave power output.

For individuals who have an unresectable primary or metastatic tumor (eg, breast, hepatic [primary or metastatic], pulmonary, renal) who receive MWA, the evidence includes case series, observational studies, cohort studies, randomized controlled trials, and systematic reviews. Relevant outcomes are overall survival, disease-specific survival, symptoms, quality of life, and treatment-related mortality and morbidity. Available studies have shown that MWA results in a wide range of complete tissue ablation (50%-100%) depending on tumor size, with complete ablation common and nearing 100% with smaller tumors (eg, ≤ 3 cm). Tumor recurrence rates at ablated sites are very low. However, tumor recurrence at nonablated sites is common and may correlate with disease state (eg, in hepatocellular carcinoma). Intraoperative and postoperative minor and major complications are low, especially when tumors are smaller and accessible. Patient selection criteria and rationale for using MWA over other established techniques (eg, surgical resection, radiofrequency ablation) are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

CODING

BlueCHiP for Medicare and Commercial Products

There are no CPT codes specific to microwave tumor ablation. Report the unlisted CPT code for the anatomic area.

RELATED POLICIES

None

PUBLISHED

Provider Update, August 2018
Provider Update, June 2017
Provider Update, May 2016
Provider Update, May 2015
Provider Update, June 2014
Provider Update, November 2013
Provider Update, May 2012

REFERENCES

1. Zhao Z, Wu F. Minimally-invasive thermal ablation of early-stage breast cancer: a systemic review. *Eur J Surg Oncol* 2010; 36 (12); 1149-55.
2. Zhou W, Zha X, Liu X et al. US-guided percutaneous microwave coagulation of small breast cancers: a clinical study. *Radiology* 2012; 263 (2); 364-73
3. Chinnaratha MA, Chuang MA, Fraser RJ, et al. Percutaneous thermal ablation for primary hepatocellular carcinoma: A systematic review and meta-analysis. *J Gastroenterol Hepatol*. Jun 25 2015. PMID 26114968
4. Ong St, Gravante G Metcalfe MS et al. Efficacy and safety of microwave ablation for primary and secondary liver malignancies: a systematic review, *Eur J Gastroenterol Hepatol* 2009; 21 (6) 599-605
5. Bertot LC, Sato M, Tateishi R et al. Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors; a systematic review. *Eur Radiol* 2011; 21(12) 2584-96

6. Abdelaziz AO, Nabeel MM, Elbaz TM, et al. Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis. *Scand J Gastroenterol*. Apr 2015;50(4):479-484. PMID 25592058
7. Vogl TJ, Farshid P, Naguib NN, et al. Ablation therapy of hepatocellular carcinoma: a comparative study between radiofrequency and microwave ablation. *Abdom Imaging*. Aug 2015;40(6):1829-1837. PMID 25601438
8. Acksteiner C, Steinke K. Percutaneous microwave ablation for early-stage non-small cell lung cancer (NSCLC) in the elderly: a promising outlook. *J Med Imaging Radiat Oncol*. Feb 2015;59(1):82-90. PMID 25335916
9. Sun YH, Song PY, Guo Y, et al. Computed tomography-guided percutaneous microwave ablation therapy for lung cancer. *Genet Mol Res*. 2015;14(2):4858-4864. PMID 25966260
10. Simo KA, Sereika SE, Newton KN et al. Laparoscopic-assisted microwave ablation for hepatocellular carcinoma: Safety and efficacy in comparison with radiofrequency ablation, *J Surg Oncol* 2011; 104 (7); 822-9
11. Ding J, Jing X, Liu J et al. Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma. *Eur J Radiol* 2013, 82(9): 1379-84.
12. Bala MM, Riemsma RP, Wolff R, et al. Microwave coagulation for liver metastases. *Cochrane Database Syst Rev*. 2013; 10:CD010163. PMID 24122576
13. Loveman E, Jones J, Clegg AJ, et al. The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation. *Health Technol Assess*. Jan 2014; 18(7):vii-viii, 1-283. PMID 24484609
14. Katsanos K, Mailli L, Krokidis M, et al. Systematic review and meta-analysis of thermal ablation versus surgical nephrectomy for small renal tumours. *Cardiovasc Intervent Radiol*. Apr 2014;37(2):427-437. PMID 24482030
15. Martin J, Athreya S. Meta-analysis of cryoablation versus microwave ablation for small renal masses: is there a difference in outcome? *Diagn Interv Radiol*. Nov-Dec 2013;19(6):501-507. PMID 24084196

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

